<DOC>
	<DOCNO>NCT00182611</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , S-1 cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving chemotherapy surgery may shrink tumor remove . It yet know whether give S-1 together cisplatin surgery effective surgery follow S-1 treat stomach cancer . PURPOSE : This randomized phase III trial study well give S-1 together cisplatin surgery work compare surgery follow S-1 treat patient stage III stomach cancer .</brief_summary>
	<brief_title>S-1 Cisplatin Treating Patients Who Are Undergoing Surgery Stage III Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient potentially resectable stage III gastric cancer treat neoadjuvant S-1 cisplatin follow gastrectomy adjuvant S-1 v neoadjuvant chemotherapy gastrectomy adjuvant S-1 . Secondary - Compare progression-free survival patient treat regimen . - Compare curative resection rate patient treat regimen . - Compare safety regimen , term postoperative complication , adverse event , treatment- surgery-related mortality rate , patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease stage ( T3 v T4 ) ECOG performance status ( 0 vs 1 ) . Patients randomize 1 2 treatment arm . - Arm I ( control ) : Patients undergo gastrectomy D2+ lymph node dissection . Patients receive adjuvant oral S-1 . - Arm II ( neoadjuvant therapy ) : Patients receive neoadjuvant oral S-1 day 1-21 cisplatin IV 2 hour day 8 . Treatment repeat every 35 day 2 course absence disease progression . Patients undergo surgery receive adjuvant S-1 arm I . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastric adenocarcinoma , include type II type III adenocarcinoma esophagogastric junction Stage III disease T3 T4 and/or N2 No stage IV disease Helical CT scan laparoscopic staging require Potentially resectable disease PATIENT CHARACTERISTICS : Age 20 Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC ≥ 4,000/mm³ , &lt; 12,000/mm³ Granulocyte count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Hepatic AST ALT ≤ 2.5 time upper limit normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine clearance ≥ 50 mL/min Pulmonary Arterial oxygen pressure ( PaO_2 ) ≥ 70 mm Hg room air Other Able take oral medication PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy gastric cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy gastric cancer Surgery No prior surgery gastric cancer Other No prior therapy gastric cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>